To live what we chose to become

SynCell News • January 21, 2021

We live in a world where the antibiotics discovery market is broken and deathly injured. A world where it can take up to 15 years to discover a new molecule and bring it to the market. But why?

The source of the new antibiotic has to be discovered, which is not a simple task. Even if there is a match, research has to lead to no-toxicity towards human beings, which does not always happen. Suppose the first bunch of clearance filters has been completed. In that case, the candidate drug has to be moved to clinical trials, meaning thousands of patients, millions of dollars, and uncountable amounts of a time that is not coming back for anyone.

We have millions of dollars, thousands of smart minds, and a clock counting backward till the next pandemic.

As such, we have a situation where there are around 40-50 antibiotics in clinical trials. Instead of becoming new drugs are just slight modifications of existing drugs and have little or non-benefit at all. Still, 250 more drugs are nowadays in preclinical trials, and around ten years will pass until they reach the first patient if approved.

We have millions of dollars, thousands of smart minds, and a clock counting backward till the next pandemic. Bacteria have an evolution on their side, which allows them to take a drug that has taken 15 years to be developed and show resistance to it in less than a year.

Can you imagine a world without antibiotics?

No investment fund, scientist, startups, or big pharma corporative are to blame: the current paradigm does not sound like a profitable way to move ahead. But can you imagine a world without antibiotics? A moment in history where the pipeline is exhausted and death? A situation where there is nothing left to treat the infection but time to mourn for a future that will never arrive?

At SynCell, we support more than ever the current research in the antibiotics space. Still, we become eager to see the possibility of that production pipeline accepting new and alternative antimicrobial drugs, such as those we hope to deliver to the public soon.

The future in the antimicrobial space will be profoundly impacted by developing new research trends, such as antimicrobial peptides, phage therapy, antibodies, or nanotechnology. As such, we become proud to provide the world with our small contribution to the fight towards the development of antibiotic resistance, with the aim of a brighter future for all of us.